Cat FIP Antiviral Treatment Welfare

Feline Infectious Peritonitis (FIP) was until recently invariably fatal. The development of antiviral drugs has transformed it into a manageable disease, dramatically improving welfare outcomes for affected cats.

Key Facts

FIP is caused by a mutated form of feline coronavirus and affects approximately 1 in 5,000 cats annually
Before antiviral treatment, FIP was uniformly fatal - cats typically died within weeks to months of diagnosis
Remdesivir, GS-441524, and molnupiravir are antiviral drugs that effectively treat FIP in the majority of cats
Treatment with GS-441524 achieves sustained remission in approximately 85% of treated cats
Treatment requires 12 weeks of daily medication (injection or oral) and at least 3 months post-treatment monitoring
BOVA UK and specialist veterinary pharmacies provide licensed antiviral preparations for FIP treatment
Treatment cost ranges from 3,000-8,000 pounds depending on treatment formulation and cat size
The unlicensed nature of some FIP antivirals previously made access difficult but regulatory approval is advancing

Welfare Considerations

FIP antiviral treatment has transformed the welfare trajectory of one of the most feared feline diseases. Previously, a diagnosis of FIP was effectively a death sentence delivered over weeks of progressive deterioration - cats with effusive FIP experienced respiratory or abdominal fluid accumulation causing significant discomfort before death. The 85% remission rate with antiviral treatment means that most cats with FIP can now return to a normal, healthy life after treatment. The primary welfare barrier is cost - treatment is expensive and not all owners can afford it. Access to treatment through pet insurance, charitable assistance, and continued improvement in drug licensing and availability is therefore a direct welfare priority.

What You Can Do

Insure your cats from kittenhood to ensure FIP treatment is financially accessible if needed
Seek specialist veterinary advice immediately if FIP is suspected - early treatment improves outcomes
Research the FIP treatment landscape including access to licensed and unlicensed antiviral preparations
Support FIP advocacy organisations including FIP Warriors who support affected cat owners
Advocate for accelerated licensing of FIP antiviral treatments to improve access and reduce cost
Donate to veterinary research charities supporting FIP treatment development and accessibility